Legal Issues

Biopharmaceutical company files preliminary injunction against Insmed, Celtrix

Published in Obesity and Diabetes Week, June 27th, 2005

Tercica, Inc. (TRCA) announced that Tercica and its co-plaintiff, Genentech, Inc., have filed a motion for a preliminary injunction against Insmed Incorporated and Celtrix, Inc., in the United States District Court for the Northern District of California.

Tercica is developing Increlex (mecasermin [rDNA origin] injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), as a treatment for short stature caused by primary IGF-1 deficiency.

The preliminary injunction seeks to prevent Insmed and its predecessor company, Celtrix, from making, using, offering to sell, or selling SomatoKine; and to compel Insmed to grant Tercica joint...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-06-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry